Ibrutinib, a covalent inhibitor of Bruton’s tyrosine kinase (BTK), is approved both as first-line therapy and for relapsed or refractory CLL, including patients harboring TP53 mutations or 17p deletions, who typically exhibit poor responses to chemoimmunotherapy. Here, BTK is linked to B-cell chronic lymphocytic leukemia.